Your Messages Inbox
Your Article Summary
See Latest ArticlesGenentech ordered to halt Rituxan trials
PharmExec, 06/19/09
An arbitrator has ruled that Genentech must halt several trials until Biogen Idec says they can move forward. In 2006, the two companies, filed for arbitration to settle whether Genentech could develop follow-on drugs to the cancer and rheumatoid arthritis drug Rituxan, without Biogen's approval. The arbitrator ruled that three of the trials must be halted, although a Phase III trial for the arthritis biologic ocrelizumab can continue.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Intravenous Drug Administration During Out-of-Hospital Cardiac Arrest: A Randomized Trial
JAMA, 11/25/09
A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimers disease: a post hoc analysis
Current Medical Research and Opinion, 11/25/09
Pandemic 2009 Influenza Update: Pandemrix data in children and adolescents from 3 to 17 years of age
GlaxoSmithKline, 11/24/09
Article Search
Sponsor